R&D: Are true drug breakthroughs a thing of the past?

John Carroll The agency is offering developers essentially an open door at the FDA to any program that qualifies, urging on R&D teams with quick responses and help adapting trials ...

FDA officials divided on Avandia safety as panel meeting looms

Carly Helfand Ahead of this week's FDA advisory panel meeting, staff reviewers backed a readjudication of the controversial RECORD trial, which found that the GlaxoSmithKline diabetes ...

AstraZeneca tosses another PhIII failure onto the scrap heap

John Carroll AstraZeneca just can't catch a break. After looking over lackluster late-stage results for its rheumatoid arthritis drug fostamatinib, the pharma giant has opted to ...

Dainippon Sumitomo Pharma Completes Construction on New Chemistry Research Building

barbara.lempert Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) announces that the construction of a new Chemistry Research Building ...

Tweets of the day, 6/3/2013

chris.truelove     by Christiane Truelove (chris.truelove@ubm.com) It’s the opening day of the American Society of Clinical Oncology (ASCO) meeting, and the tweets have been ...

Rencarex Improves Disease Free Survival

barbara.lempert Phase III ARISER data for the adjuvant treatment of clear cell renal cancer with RENCAREX® including retrospective subgroup analysis presented at ASCO •    RENCAREX® ...

Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin

barbara.lempert Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO Québec ...

Dr. Reddy’s, Fujifilm pull plug on Japanese joint venture

Damian Garde After almost two years of discussions and dealmaking, Fujifilm and Dr. Reddy's Laboratories have called off their plot to team up on generics in Japan. FiercePharma ...

AstraZeneca’s selumetinib looks promising for rare cases of eye melanoma

John Carroll FierceBiotech News

Shire will stay in Wayne, Pa.

barbara.lempert Drugmaker Shire will stay in Wayne PHILADELPHIA, May 31, 2013 (PHILADELPHIA INQUIRER)–Drugmaker Shire P.L.C. said Thursday it had halted plans to build ...

Big Ten Universities Form Big Ten Cancer Research Consortium

barbara.lempert Big Ten universities form Big Ten Cancer Research Consortium INDIANAPOLIS, May 31, 2013 /PRNewswire-USNewswire/ — In athletics, the Big Ten universities compete ...

Will Hepatitis C Become The Next Battleground Over Compulsory Licenses?

esilverman Will the new crop of hepatitis C treatments form the next battleground between the pharmaceutical industry, poor nations and patient advocates? A new report from ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS